▶ THYMOSIN Α-1 · SUBTOPIC · SAFETY PROFILE

THYMOSIN α-1 Safety Profile

For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of THYMOSIN α-1.

OBSERVED ADVERSE EVENTS IN LITERATURE

The following adverse events have been observed in trials or animal studies of THYMOSIN α-1. Severity, frequency, and attribution depend on the source publication.

• Generally well-tolerated
• Mild injection-site reactions
• Rare flu-like symptoms

DRUG INTERACTIONS

The following interactions are reported in or theorised from the published mechanism for THYMOSIN α-1.

• Immunosuppressive medications (theoretical)

CONTRAINDICATIONS REPORTED IN LITERATURE

Contraindications recorded for THYMOSIN α-1 in the published record:

• Active autoimmune disease (theoretical)

FDA REGULATORY STATUS

Not FDA-approved. Research-use only in the United States.

WADA REGULATORY STATUS

Not currently listed on the WADA Prohibited List.

OTHER JURISDICTIONS

International · Approved as Zadaxin (thymalfasin) in 35+ countries for chronic hepatitis B/C and as an immune-system adjuvant.

SAFETY Q+A FROM LITERATURE

CITED LITERATURE

The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.

• Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther 2009. PMID 19392576. link
• Wu J, Zhou L, Liu J, et al.. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicentre, single-blind, randomized and controlled trial. Crit Care 2013. PMID 23327199. link
• Liu Y, Pan Y, Hu Z, et al.. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019. Clin Infect Dis 2020. PMID 32442287. link

RELATED PAGES

▶ LAST UPDATED · 2026-05-19